Pulling iclaprim out of the ashes
This article was originally published in Scrip
Seven years ago, the antibiotic iclaprim looked dead in the water. Seven months ago, Motif Bio was barely a blip on the biotech radar. But seven years is a long time in the antibiotic space, and seven months is a long time in biotech. Things are looking very different for both iclaprim and Motif. Scrip met with CEO Graham Lumsden, formerly of Merck & Co, and chairman Richard Morgan, CEO of majority shareholder Amphion Innovations, to get the details.
You may also be interested in...
Positive data from a second Phase III trial sets up Motif Bio for an NDA filing by the end of the year for novel antibiotic iclaprim – but success for the product has been a long time coming.
Biotech firm hopes its once-shelved antibiotic will provide a therapeutic option for renally impaired patients with serious skin infections. With only one previous DHFR inhibitor ever approved, Motif also anticipates that iclaprim will offer an option for multidrug-resistant infections.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.